GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (OTCPK:MYPHY) » Definitions » Forward PE Ratio

Mayne Pharma Group (Mayne Pharma Group) Forward PE Ratio : 0.00 (As of Jun. 08, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Mayne Pharma Group Forward PE Ratio?

Mayne Pharma Group's Forward PE Ratio for today is 0.00.

Mayne Pharma Group's PE Ratio without NRI for today is 0.00.

Mayne Pharma Group's PE Ratio for today is 0.00.


Mayne Pharma Group Forward PE Ratio Historical Data

The historical data trend for Mayne Pharma Group's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group Forward PE Ratio Chart

Mayne Pharma Group Annual Data
Trend
Forward PE Ratio

Mayne Pharma Group Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Mayne Pharma Group's Forward PE Ratio

For the Drug Manufacturers - General subindustry, Mayne Pharma Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mayne Pharma Group's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's Forward PE Ratio falls into.



Mayne Pharma Group Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Mayne Pharma Group  (OTCPK:MYPHY) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Mayne Pharma Group Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mayne Pharma Group (Mayne Pharma Group) Business Description

Traded in Other Exchanges
Address
1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.